AbbVie ABBV Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.82B+2.7% | $61.16B+2.5% | $59.64B+2.3% | $58.33B+1.7% | $57.37B+1.8% | ||
| $18.42B+1.2% | $18.2B+0.9% | $18.05B+6.4% | $16.96B+0.9% | $16.81B-0.5% | ||
| $44.4B+3.4% | $42.96B+3.3% | $41.6B+0.5% | $41.37B+2.0% | $40.56B+2.9% | ||
| 70.7%+0.4pp | 70.2%+0.5pp | 69.7%-1.2pp | 70.9%+0.2pp | 70.7%+0.7pp | ||
| $14.3B+2.0% | $14.01B+0.3% | $13.97B-4.4% | $14.61B-0.8% | $14.73B-0.1% | ||
| $47.49B+3.0% | $46.09B-8.9% | $50.6B+6.8% | $47.36B+0.1% | $47.3B+0.2% | ||
| $15.33B+1.7% | $15.08B— | —— | —— | —— | ||
| 24.4%-0.2pp | 24.6%— | —— | —— | —— | ||
| $5.98B-9.4% | $6.6B— | —— | —— | —— | ||
| $2.33B-1.3% | $2.36B+422% | -$735M+0.8% | -$741M-27.5% | -$581M-1.9% | ||
| $3.64B-14.0% | $4.23B+77.0% | $2.39B-36.5% | $3.76B-10.3% | $4.2B-1.9% | ||
| 5.8%-1.1pp | 6.9%+2.9pp | 4%-2.4pp | 6.5%-0.9pp | 7.3%-0.3pp | ||
| $2.03-14.0% | $2.36+78.8% | $1.32-37.1% | $2.10-10.6% | $2.35-2.1% | ||
| $23.43B+0.7% | $23.28B— | —— | —— | —— | ||
| 37.3%-0.8pp | 38.1%— | —— | —— | —— | ||
| $15.33B+1.7% | $15.08B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AbbVie's revenue?
- AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
- Is AbbVie profitable?
- AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
- What are AbbVie's profit margins?
- Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
- What is AbbVie's earnings per share?
- AbbVie's diluted EPS over the trailing twelve months is $2.03.
- Where does AbbVie's income statement data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
